Mechanism of action
Ondansetron selectively blocks serotonin type 3 (5-HT3) receptors both in the central nervous system and peripherally. The antiemetic effect results from antagonism at two key sites:
Central mechanism: Ondansetron blocks 5-HT3 receptors in the chemoreceptor trigger zone (CTZ) located in the area postrema of the medulla. This zone lies outside the blood-brain barrier and detects emetogenic substances in the blood and cerebrospinal fluid. By preventing serotonin from activating these receptors, ondansetron inhibits the signals that trigger vomiting.
Peripheral mechanism: The drug also blocks 5-HT3 receptors on vagal afferent neurons in the gastrointestinal tract. Chemotherapeutic agents and surgical manipulation cause enterochromaffin cells in the gut to release serotonin, which normally activates vagal afferents that signal the vomiting center. Ondansetron interrupts this pathway.
Ondansetron does not have dopaminergic, histaminergic, or significant cholinergic activity, distinguishing it from older antiemetics. This selectivity results in fewer central nervous system and extrapyramidal side effects compared to dopamine antagonists like metoclopramide.
- Ondansetron is a selective 5-HT3 receptor antagonist that blocks serotonin receptors in the CTZ and gut vagal afferents
- Main uses are prevention of chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea and vomiting (PONV)
- The most significant adverse effect is QT prolongation and risk of torsades de pointes, especially with IV doses exceeding 16 mg
- Not effective for motion sickness because vestibular nausea is mediated by histamine and muscarinic receptors, not 5-HT3
- Risk of serotonin syndrome when combined with SSRIs, SNRIs, tramadol, or other serotonergic agents
- Constipation is common due to blockade of 5-HT3 receptors that normally promote GI motility
- Contraindicated with apomorphine due to risk of profound hypotension and loss of consciousness
- Most effective when given prophylactically before chemotherapy or surgery rather than after nausea develops
Indications
Ondansetron is indicated for:
- Chemotherapy-induced nausea and vomiting (CINV): Prevention of nausea and vomiting associated with moderately to highly emetogenic cancer chemotherapy, including cisplatin-based regimens. Most effective when given before chemotherapy administration.
- Postoperative nausea and vomiting (PONV): Prevention and treatment of PONV in surgical patients. Typically administered at the end of surgery or when nausea occurs in the recovery room.
- Radiation-induced nausea and vomiting: Prevention of nausea and vomiting associated with radiotherapy, particularly total body irradiation and fractionated abdominal radiation.
Ondansetron is used off-label for gastroenteritis-related vomiting in children and adults, hyperemesis gravidarum in pregnancy (though not FDA-approved for this indication), and alcohol use disorder. The evidence for gastroenteritis is strongest in pediatric populations, where it reduces vomiting episodes and the need for intravenous hydration.
Pharmacokinetics
Absorption: Ondansetron is well absorbed after oral administration with bioavailability of approximately 60% due to first-pass metabolism. Peak plasma concentrations occur within 1.5 to 2 hours. Food slightly increases the extent of absorption but does not significantly affect clinical efficacy.
Distribution: The volume of distribution is large (approximately 140 L), indicating extensive tissue distribution. Plasma protein binding is 70-76%. Ondansetron crosses the placenta and is present in breast milk in small amounts.
Metabolism: Ondansetron undergoes extensive hepatic metabolism via multiple cytochrome P450 enzymes, primarily CYP3A4, CYP2D6, and CYP1A2. The drug is metabolized by hydroxylation followed by glucuronide or sulfate conjugation. Multiple metabolic pathways mean that inhibition of a single enzyme typically does not dramatically alter clearance.
Excretion: Approximately 5% of a dose is excreted unchanged in urine. The elimination half-life is 3 to 4 hours in healthy adults, but increases to 5 to 6 hours in patients over 75 years of age and in those with severe hepatic impairment. Renal impairment does not significantly affect pharmacokinetics.
Special populations: Clearance is reduced in elderly patients and those with moderate to severe liver disease, warranting dose adjustment in severe hepatic impairment.
Adverse effects
Ondansetron is generally well tolerated, but several adverse effects are clinically important:
Cardiovascular:
- QT prolongation: The most significant adverse effect. Ondansetron blocks cardiac potassium channels (hERG), leading to QTc interval prolongation and potential torsades de pointes, particularly with intravenous administration and higher doses. Risk increases with electrolyte abnormalities (hypokalemia, hypomagnesemia), concomitant QT-prolonging drugs, and underlying cardiac disease.
- Arrhythmias including atrial fibrillation and bradycardia have been reported rarely.
Neurological:
- Headache (9-27% of patients): The most common adverse effect overall.
- Dizziness and lightheadedness
- Serotonin syndrome: Rare but serious when combined with other serotonergic agents (SSRIs, SNRIs, MAOIs, tramadol). Presents with altered mental status, autonomic instability, and neuromuscular abnormalities.
Gastrointestinal:
- Constipation (6-11%): Results from 5-HT3 blockade in the gut, which normally promotes motility.
- Diarrhea
- Elevated liver enzymes (transient and usually mild)
Other effects:
- Fatigue and malaise
- Fever
- Hypersensitivity reactions including anaphylaxis (rare)
- Transient visual disturbances (blurred vision)
Serotonin syndrome is a high-yield exam concept when ondansetron is combined with SSRIs or other serotonergic medications.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to ondansetron or other 5-HT3 receptor antagonists
- Concomitant use with apomorphine (profound hypotension and loss of consciousness reported)
Warnings and precautions:
Cardiac: Ondansetron prolongs the QT interval in a dose-dependent manner. Use with caution in patients with:
- Congenital long QT syndrome
- Electrolyte abnormalities (hypokalemia, hypomagnesemia) — correct before administration
- Heart failure, bradyarrhythmias
- Concomitant medications that prolong QT interval or inhibit ondansetron metabolism
The risk is highest with intravenous doses exceeding recommended amounts. Single intravenous doses should not exceed 16 mg due to QT concerns.
Hepatic impairment: Dose reduction is recommended in patients with severe hepatic dysfunction due to decreased clearance and prolonged half-life. In moderate impairment, ondansetron exposure increases but dose adjustment is typically not required.
Serotonin syndrome: Risk increases when combined with other serotonergic drugs. Monitor for mental status changes, autonomic instability, and neuromuscular symptoms.
Pregnancy and lactation: Ondansetron is pregnancy category B (no controlled human data, but animal studies show no harm). It is widely used off-label for hyperemesis gravidarum, though some observational studies have suggested a possible small increased risk of oral clefts when used in the first trimester; evidence remains conflicting. The drug is excreted in breast milk in small amounts; use with caution during breastfeeding.
Masking of progressive ileus: Because ondansetron suppresses nausea, it may mask signs of bowel obstruction or gastric distension, particularly postoperatively.
Drug interactions
Pharmacodynamic interactions:
- QT-prolonging drugs: Additive risk of QTc prolongation and arrhythmias when combined with antiarrhythmics (amiodarone, sotalol), macrolide antibiotics (azithromycin, erythromycin), fluoroquinolones (moxifloxacin), antipsychotics (haloperidol, ziprasidone), and tricyclic antidepressants. Avoid combination or monitor ECG closely.
- Serotonergic drugs: Increased risk of serotonin syndrome when combined with SSRIs, SNRIs, MAOIs, tricyclic antidepressants, tramadol, fentanyl, lithium, triptans, and St. John's wort. The risk is greatest when multiple serotonergic agents are used concurrently.
- Apomorphine: Contraindicated due to reports of profound hypotension and loss of consciousness.
Pharmacokinetic interactions:
- CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John's wort): Increase ondansetron metabolism, reducing plasma concentrations and potentially decreasing efficacy. Higher ondansetron doses may be needed.
- CYP3A4 inhibitors (ketoconazole, erythromycin, clarithromycin, protease inhibitors): May increase ondansetron concentrations, though the clinical significance is usually minor due to multiple metabolic pathways.
- CYP2D6 polymorphism: Poor metabolizers may have slightly increased exposure, but dose adjustment is typically not required.
Ondansetron does not significantly affect the pharmacokinetics of chemotherapeutic agents or other medications, making it a relatively safe choice in polypharmacy settings.
Clinical pearls
- Timing matters: Ondansetron is most effective when given prophylactically before chemotherapy or at the end of surgery, rather than waiting for nausea to develop. For CINV, administer 30 minutes before chemotherapy.
- Limited efficacy for motion sickness: Despite being an antiemetic, ondansetron is not effective for motion sickness or vestibular-mediated nausea because these conditions are primarily mediated by histamine (H1) and muscarinic receptors, not 5-HT3 receptors. Antihistamines or scopolamine are preferred.
- Constipation management: The constipating effect can be problematic in patients receiving opioid-based pain management. Consider prophylactic laxatives in at-risk populations.
- ECG monitoring: Check baseline ECG and electrolytes in patients with cardiac risk factors before administering ondansetron, especially intravenously. The QT effect is dose-dependent and most pronounced with IV administration.
- Oral disintegrating tablets (ODT): Useful for patients with difficulty swallowing or active vomiting. They dissolve rapidly on the tongue without water, though they are absorbed in the GI tract, not sublingually.
- Pediatric use in gastroenteritis: A single dose of ondansetron reduces vomiting and the need for IV hydration in children with acute gastroenteritis, but does not reduce diarrhea or hasten recovery. It is not a substitute for oral rehydration therapy.
- Breakthrough nausea: If ondansetron fails, consider adding a medication with a different mechanism (dopamine antagonists like metoclopramide, NK1 receptor antagonists like aprepitant, or corticosteroids like dexamethasone). Multimodal antiemetic therapy is often superior for highly emetogenic chemotherapy.
- Cost-effectiveness: Ondansetron is now available generically and is much more affordable than when first introduced, making it accessible for routine PONV prophylaxis.
- No addiction potential: Unlike many antiemetics with sedative properties, ondansetron has no abuse potential and is not a controlled substance.
Practice questions
1. A 45-year-old woman with breast cancer is scheduled to begin chemotherapy with doxorubicin and cyclophosphamide. To prevent chemotherapy-induced nausea and vomiting, she is prescribed ondansetron. Two weeks later, she develops confusion, tremor, diaphoresis, and hyperreflexia. Her medications also include fluoxetine for depression, which she has been taking for 6 months. Which of the following best explains her current presentation?
2. A 68-year-old man undergoes elective hip replacement surgery. He receives ondansetron intravenously at the end of the procedure for prevention of postoperative nausea. His past medical history includes atrial fibrillation treated with amiodarone and heart failure. Twelve hours postoperatively, telemetry shows a prolonged QTc interval of 520 ms (baseline 440 ms). Which of the following factors most likely contributed to this finding?
3. A 32-year-old woman in her first trimester of pregnancy presents with severe nausea and vomiting consistent with hyperemesis gravidarum. She has lost 8 pounds and shows signs of dehydration. Conservative measures with dietary modifications and pyridoxine have failed. After IV fluid resuscitation, her obstetrician considers prescribing ondansetron. Which of the following statements is most accurate regarding ondansetron use in this patient?
Frequently asked questions
How does ondansetron work?
Ondansetron works by selectively blocking serotonin 5-HT3 receptors in two locations: the chemoreceptor trigger zone in the brainstem and on vagal nerve terminals in the gastrointestinal tract. When chemotherapy drugs or anesthetics cause cells to release serotonin, that serotonin normally activates these receptors to trigger nausea and vomiting. By blocking the receptors, ondansetron prevents the nausea signal from being transmitted to the vomiting center in the brain.
What are the side effects of ondansetron?
The most common side effects are headache (occurring in 9-27% of patients) and constipation. The most serious adverse effect is QT interval prolongation, which can lead to a dangerous heart rhythm called torsades de pointes, particularly at higher intravenous doses or in patients with heart disease or electrolyte imbalances. Other side effects include dizziness, fatigue, and rarely serotonin syndrome when combined with other serotonergic medications like SSRIs. Most patients tolerate ondansetron well.
Is ondansetron a controlled substance?
No, ondansetron is not a controlled substance and has no abuse or addiction potential. Unlike some older antiemetics that have sedative or euphoric effects, ondansetron works selectively on serotonin receptors involved in nausea without affecting dopamine, opioid, or other receptors associated with dependence. It can be prescribed without DEA registration and has no restrictions beyond standard prescription requirements.
Can ondansetron prolong the QT interval?
Yes, ondansetron can prolong the QT interval in a dose-dependent manner by blocking cardiac potassium channels. This effect is most pronounced with intravenous administration and at doses exceeding 16 mg. QT prolongation increases the risk of torsades de pointes, a potentially fatal arrhythmia. The risk is higher in patients with underlying heart conditions, electrolyte abnormalities (low potassium or magnesium), congenital long QT syndrome, or those taking other QT-prolonging medications. ECG monitoring and electrolyte correction are recommended in high-risk patients.
Ondansetron vs metoclopramide — what is the difference?
Ondansetron and metoclopramide are both antiemetics but work through different mechanisms. Ondansetron blocks serotonin 5-HT3 receptors and is preferred for chemotherapy-induced and postoperative nausea, with fewer side effects overall. Metoclopramide blocks dopamine D2 receptors and also promotes gastric emptying, making it useful for gastroparesis and reflux-related nausea. However, metoclopramide carries a higher risk of extrapyramidal side effects (dystonia, tardive dyskinesia) and central nervous system effects like drowsiness and depression. Ondansetron has better tolerability but can cause QT prolongation, while metoclopramide has movement disorder risks but not cardiac effects.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A04AA01
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.